TABLE 2. Adverse reactions reported by persons who received an additional dose of COVID-19 vaccine (N = 22,191)* and completed at least one v-safe health check-in survey on days 0–7 after vaccination, by primary vaccination series and manufacturer of subsequent dose received — United States, August 12–September 19, 2021.
| Reaction | Moderna, %† (n = 10,477) |
Pfizer-BioNTech, %† (n = 11,284) |
Janssen, %†,§ (n = 174) |
Total (N = 22,191) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose 3 Moderna (n = 10,453; 98.6%) | Dose 3 Pfizer-BioNTech (n = 144; 1.4%) | Dose 3 Janssen (n = 4; 0.04%) | Dose 3 Pfizer-BioNTech (n = 11,209; 98.2%) | Dose 3 Moderna (n = 197; 1.7%) | Dose 3 Janssen (n = 6; 0.1%) | Dose 2 Janssen (n = 48; 27.0%) | Dose 2 Moderna (n = 64; 36.0%) | Dose 2 Pfizer-BioNTech (n = 66; 37.1%) | ||
|
Days since primary series, median (IQR)
|
182 (164–198) |
183 (161–204) |
173 (141–182) |
183 (157–209) |
186 (161–217) |
123 (113–182) |
84 (16–136) |
156 (140–164) |
150 (136–167) |
182 (160–202)
|
|
Any injection site reaction
|
80.9
|
64.6
|
75.0
|
69.4
|
81.7
|
83.3
|
25.0
|
70.3
|
80.3
|
74.9
|
| Itching |
20.0 |
11.8 |
0 |
8.4 |
10.2 |
16.7 |
10.4 |
6.3 |
7.6 |
13.9
|
| Pain |
75.9 |
60.4 |
75.0 |
66.6 |
80.2 |
83.3 |
20.8 |
68.8 |
74.2 |
71.0
|
| Redness |
25.2 |
8.3 |
0 |
9.8 |
20.8 |
16.7 |
6.3 |
7.8 |
12.1 |
17.1
|
| Swelling |
33.6 |
17.4 |
0 |
16.8 |
30.5 |
16.7 |
6.3 |
12.5 |
18.2 |
24.8
|
|
Any systemic reaction
|
75.2
|
59.7
|
50.0
|
65.1
|
76.1
|
100
|
31.3
|
68.8
|
63.6
|
69.9
|
| Abdominal pain |
8.4 |
3.5 |
0 |
6.4 |
8.1 |
16.7 |
4.2 |
3.1 |
6.1 |
7.3
|
| Myalgia |
49.8 |
29.2 |
0 |
36.3 |
49.2 |
50.0 |
20.8 |
45.3 |
33.3 |
42.7
|
| Chills |
31.3 |
8.3 |
50.0 |
17.5 |
33.5 |
50.0 |
8.3 |
23.4 |
10.6 |
24.1
|
| Diarrhea |
9.9 |
7.6 |
0 |
9.0 |
9.6 |
16.7 |
8.3 |
6.3 |
9.1 |
9.4
|
| Fatigue |
61.8 |
44.4 |
0 |
51.0 |
60.9 |
83.3 |
14.6 |
48.4 |
50.0 |
56.0
|
| Fever |
36.4 |
20.1 |
50.0 |
22.2 |
37.1 |
50.0 |
6.3 |
37.5 |
12.1 |
29.0
|
| Headache |
49.0 |
31.1 |
0 |
38.4 |
49.7 |
83.3 |
18.8 |
35.9 |
40.9 |
43.4
|
| Joint pain |
33.0 |
18.8 |
0 |
23.0 |
31.0 |
33.3 |
16.7 |
20.3 |
19.7 |
27.7
|
| Nausea |
18.8 |
10.4 |
25.0 |
13.6 |
21.3 |
33.3 |
8.3 |
9.4 |
18.2 |
16.1
|
| Rash |
2.3 |
0.7 |
0 |
1.9 |
2.5 |
0 |
4.2 |
1.6 |
1.5 |
2.1
|
| Vomiting |
2.2 |
2.1 |
25.0 |
1.4 |
2.0 |
0 |
2.1 |
0 |
0 |
1.7
|
|
Any health impact
|
39.2
|
19.4
|
0
|
25.2
|
39.1
|
33.3
|
16.7
|
28.1
|
24.2
|
31.8
|
| Unable to perform normal daily activities |
35.2 |
18.1 |
0 |
22.1 |
33.0 |
33.3 |
10.4 |
25.0 |
15.2 |
28.3
|
| Unable to work or attend school |
13.7 |
4.9 |
0 |
9.0 |
21.3 |
16.7 |
10.4 |
6.3 |
13.6 |
11.3
|
| Needed medical care |
2.1 |
1.4 |
0 |
1.5 |
3.0 |
0 |
6.3 |
0 |
0 |
1.8
|
| Telehealth |
0.9 |
0.7 |
0 |
0.7 |
1.0 |
0 |
2.1 |
0 |
0 |
0.8
|
| Clinic |
0.7 |
0.7 |
0 |
0.6 |
0.5 |
0 |
4.2 |
0 |
0 |
0.6
|
| Emergency visit |
0.2 |
0 |
0 |
0.2 |
0 |
0 |
4.2 |
0 |
0 |
0.2
|
| Hospitalization | 0.05 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0.1 |
Abbreviation: IQR = interquartile range.
* Percentage of registrants who completed at least one v-safe health check-in survey on days 0–7 after vaccination.
† Primary vaccination series.
§ Includes persons who received a primary Janssen single-dose and one additional dose of vaccine from the listed manufacturers.